£890.00

It has never been this cheap. We have no record of a lower price.

£890 today · cheaper than every other day in the last 3 months

The 2027-2032 World Outlook for Chronic Obstructive Pulmonary Disease Treatments

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 56 days · 56 data points (no recent data)

Historical
Generating forecast…
£890.00 £845.50 £863.30 £881.10 £898.90 £916.70 £934.50 22 August 2026 04 September 2026 18 September 2026 02 October 2026 16 October 2026
View at Amazon ↗

Price data last checked 35 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 56 days • 1 price levels

Days at Price
56 days 0 14 28 42 56 £890 Days at Price

Price Analysis

Most common price: £890 (56 days, 100.0%)

Price range: £890 - £890

Price levels: 1 different prices over 56 days

Description

This study covers the world outlook for chronic obstructive pulmonary disease treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of chronic obstructive pulmonary disease treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Mylan NV, Novartis International, Orion, Sunovion Pharmaceuticals, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2026).

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
05 January 2026
Listed Since
05 February 2026

Similar Products You Might Like

The 2026-2031 World Outlook for Chronic Obstructive Pulmonary Disease Treatments
96% match

The 2026-2031 World Outlook for Chronic Obstructive Pulmonary Disease Treatments

£885.00 16 Oct 2026
The 2027-2032 World Outlook for Clostridium Difficile Infection Treatments
95% match

The 2027-2032 World Outlook for Clostridium Difficile Infection Treatments

£890.00 22 Oct 2026
The 2027-2032 World Outlook for Glaucoma Pharmaceuticals
94% match

The 2027-2032 World Outlook for Glaucoma Pharmaceuticals

£890.00 21 Oct 2026
The 2027-2032 World Outlook for Cardiac Rhythm Management
93% match

The 2027-2032 World Outlook for Cardiac Rhythm Management

£890.00 27 Oct 2026
The 2027-2032 World Outlook for Interventional Radiology Products
93% match

The 2027-2032 World Outlook for Interventional Radiology Products

£890.00 10 Sep 2026
The 2027-2032 World Outlook for Cholestrol Lowering Drugs
93% match

The 2027-2032 World Outlook for Cholestrol Lowering Drugs

£890.00 24 Oct 2026
The 2027-2032 World Outlook for Menopausal Hot Flashes Therapies
93% match

The 2027-2032 World Outlook for Menopausal Hot Flashes Therapies

£890.00 27 Oct 2026
The 2027-2032 World Outlook for CPR Training Manikins
93% match

The 2027-2032 World Outlook for CPR Training Manikins

£890.00 26 Oct 2026
The 2027-2032 World Outlook for Interventional Radiology Systems
93% match

The 2027-2032 World Outlook for Interventional Radiology Systems

£890.00 08 Sep 2026
The 2027-2032 World Outlook for IBD (Ulcerative Colitis and Crohn's Disease) Treatments
93% match

The 2027-2032 World Outlook for IBD (Ulcerative Colitis and Crohn's Disease) Treatments

£890.00 16 Oct 2026
The 2027-2032 World Outlook for Medical Exoskeletons
93% match

The 2027-2032 World Outlook for Medical Exoskeletons

£890.00 24 Oct 2026
The 2027-2032 World Outlook for Topical Vitiligo Therapeutics
93% match

The 2027-2032 World Outlook for Topical Vitiligo Therapeutics

£890.00 29 Oct 2026
The 2027-2032 World Outlook for Dehydrating Breathers
93% match

The 2027-2032 World Outlook for Dehydrating Breathers

£890.00 11 Nov 2026
The 2027-2032 World Outlook for Medium Chain Triglycerides
93% match

The 2027-2032 World Outlook for Medium Chain Triglycerides

£890.00 23 Oct 2026
The 2027-2032 World Outlook for Drugs for Rheumatoid Arthritis
93% match

The 2027-2032 World Outlook for Drugs for Rheumatoid Arthritis

£890.00 30 Oct 2026
The 2027-2032 World Outlook for Carboxy Methyl Cellulose
93% match

The 2027-2032 World Outlook for Carboxy Methyl Cellulose

£890.00 04 Nov 2026
The 2027-2032 World Outlook for Mixed Nocturia
93% match

The 2027-2032 World Outlook for Mixed Nocturia

£890.00 22 Oct 2026
The 2027-2032 World Outlook for Bloodstream Infection Testing
93% match

The 2027-2032 World Outlook for Bloodstream Infection Testing

£890.00 27 Oct 2026
The 2027-2032 World Outlook for Conventional Bloodstream Infection Testing
93% match

The 2027-2032 World Outlook for Conventional Bloodstream Infection Testing

£890.00 27 Oct 2026
The 2027-2032 World Outlook for Formaldehydes
93% match

The 2027-2032 World Outlook for Formaldehydes

£890.00 09 Sep 2026
The 2027-2032 World Outlook for High-Density Multiplexed Diagnostic Assays
93% match

The 2027-2032 World Outlook for High-Density Multiplexed Diagnostic Assays

£890.00 09 Sep 2026
The 2027-2032 World Outlook for Nocturia Drugs
93% match

The 2027-2032 World Outlook for Nocturia Drugs

£890.00 22 Oct 2026
The 2027-2032 World Outlook for Diaper Rash Treatment Products
92% match

The 2027-2032 World Outlook for Diaper Rash Treatment Products

£890.00 21 Oct 2026
The 2027-2032 World Outlook for Medical Bionic Implants and Exoskeletons
92% match

The 2027-2032 World Outlook for Medical Bionic Implants and Exoskeletons

£890.00 27 Oct 2026